We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Add this topic to your myFT Digest for news straight to your inbox
London-listed group has signed 50% more clients for its complex cell and gene therapy since end of last year
New three-year contract in place if UK drugmaker continues to manufacture the jab
Companies analysis from our sister publication
Shares slide as London-listed group announces ‘pause’ in vaccine manufacturing
Oxford Biomedica plans to use earnings from AstraZeneca jab to boost own medicines business
Tech giant rolls out new system to analyse vast volumes of biomedical data
One of the UK’s oldest biotechs enters exclusive worldwide licensing agreement
Tie-ups with big pharma are set to propel revenues to new heights
Earnings a fifth higher than a year earlier
Latest directors’ deals at Oxford BioMedica, Advanced Oncotherapy and Ultra Electronics
Swiss drugmaker will work with UK gene therapy specialist on leukaemia drug
Timely selling, and dividend reinvesting, makes a difference
A fox and a robin teach me to seek out stock market rewards, says Kevin Goldstein-Jackson
My interest in GW pharmaceuticals has been reawakened, writes Kevin Goldstein-Jackson
It’s increasingly difficult for private investors to receive company reports
Recent events in the Middle East and the heartbreaking situation in Japan have continued my cautious stance
My Portfolio: There are times when a flurry of selling activity is justified
International Edition
